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Abstract
Background: Sexual transmission of Hepatitis C virus (HCV) in men who have sex with men (MSM) and its
interaction with HIV status, sexually transmitted infections and sexual behaviour is poorly understood. We assessed
the incidence and predictors of HCV infection in HIV positive MSM.
Methods: The electronic medical record and laboratory results from HIV positive MSM in care at a large urban
public specialist HIV clinic embedded in a sexual health centre in Melbourne Australia were collected. Patients with
two or more HCV antibody tests between January 2008 and March 2016 and with no record of injecting drug use
were included. The HCV exposure intervals were the periods between a negative HCV test and the next HCV test.
We compared HCV exposure intervals temporally associated with and without newly acquired syphilis or anorectal
chlamydia. HCV exposure intervals were also categorised as being before or after HIV virological suppression and by
most recent and nadir CD4 cell count.
Results: Thirty seven new HCV infections were diagnosed in 822 HIV positive MSM with no history of injecting
drug use over 3114 person years (PY) of follow-up. Mean age was 43.1 years (±12.5) and mean CD4 cell count nadir
was 362 cells/uL (±186). The incidence of HCV infection in the study population was 1.19/100PY (0.99–1.38). The
incidence in exposure periods temporally close to new syphilis infection was 4.72/100PY (3.35–6.08) and to new
anorectal chlamydia infection was 1.37/100PY (0.81–1.93). The incidence in men without supressed viral load was 3.
19/100PY (1.89–4.49). In the multivariate Cox regression analysis only younger age (aHR 0.67 (0.48–0.92)), exposure
periods temporally associated to new syphilis infection (aHR 4.96 (2.46–9.99)) and higher CD4 cell count nadir (aHR
1.26 per 100 cells/uL (1.01–1.58)) were associated with increased risk of HCV infection. During the study period the
incidence of syphilis increased dramatically but the incidence of HCV infection remained the same.
Conclusions: Incidence of HCV infection is associated with syphilis but not anorectal chlamydia which suggests a
biological rather than behavioural risk modification. Rising syphilis incidence may offset declines in HCV
transmission through HCV treatment as prevention.
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Background
Sexual transmission of Hepatitis C virus (HCV), particularly
amongst men who have sex with men (MSM), is now well
established [1]. HIV-positive MSM are at highest risk, with
seroprevalence up to 9% observed in this group [2, 3].
A number of factors have been associated with sexual,
and presumed permucosal, transmission in MSM but it
is difficult to separate out the relative contribution of
each risk factor due to their interrelationship. Specific-
ally, it is not clear how behavioural and biological factors
influence transmission probability. Condomless receptive
anal intercourse, practices that potentially expose the
anorectal mucosa to blood (such as fisting, sex toys and
douching) and a history of syphilis have all been associated
with increased HCV risk amongst MSM [4–8]. Condom-
less receptive anal sex is also associated with an increased
risk of anorectal chlamydia [9, 10]. However, anorectal
chlamydia is not usually associated with genital ulceration
[11, 12]. Syphilis is also associated with condomless recep-
tive anal sex [13]. Unlike anorectal chlamydia, it is also
associated with genital ulceration and is thus a marker of
both behavioural and biological susceptibility. Similarly,
how host factors related to HIV infection, like immuno-
suppression, viremia, antiretroviral therapy (ART), viro-
logical suppression and immune recovery, affect risk of
sexual acquisition of HCV has not been studied.
The objective of this study was examine incidence of
sexually transmitted HCV infection in a population of
HIV positive MSM and to determine whether host bio-
logical factors, recent sexually transmitted infection (STI)
associated with sexual behaviour but not with increased
biological risk of infection (i.e. anorectal chlamydia) or a
recent STI associated with both sexual behaviour and bio-
logical risk (i.e. syphilis) predicted it.
Methods
We undertook a retrospective cohort study using the re-
cords of HIV-positive patients at the Melbourne Sexual
Health Centre (MSHC) in the Australian state of Victoria.
MSHC is a large publicly funded sexual health centre with
an embedded specialist HIV clinic. Approximately 20% of
the estimated 6300 individuals living with HIV in Victoria
are current receiving care at MSHC [14].
MSHC uses a customised electronic medical record
(Clinical Patient Management System, CPMS) which re-
cords detailed demographic, clinical and treatment history
and results from investigations performed on site. CPMS
contains all clinical data on all patients in care. The
Melbourne Diagnostic Unit Public Health Laboratory
(MDU PHL, University of Melbourne) provides onsite la-
boratory services including testing of microbiological
specimens for Neisseria gonorrhoeae (Nucleic acid amp-
lification testing (NAAT) and culture) and Chlamydia
trachomatis (NAAT). The Victorian Infectious Diseases
Reference Laboratory (VIDRL) is contracted to perform
all off-site laboratory biochemistry testing including
serology, virology and CD4 cell counts.
Data extracted from the electronic record included
age, sex, country of birth, risk factor for HIV acquisi-
tion and results of anorectal chlamydia by NAAT.
Anorectal chlamydia was chosen because it is associ-
ated with condomless receptive anal intercourse, which
has also been associated with HCV infection, but not
usually with a significant breach in the anorectal mu-
cosa, i.e. ulceration, and because highly sensitive NAAT
detection was used throughout the study period [9–12].
Gonorrhoea was not chosen because there was a
change in detection method from culture to NAAT
testing during the study period. Country of birth was
defined as being within or outside Australia and New
Zealand because of the large numbers of patients born
in New Zealand and the similar HIV epidemiology in
that country [15]. Data provided by the external labora-
tory included HIV viral load, CD4 cell count, HCV anti-
body and RNA testing, liver function tests and HBV
serology for all HIV-positive patients at MSHC from
January 1st 2002 to March 31st 2016. MSHC began an-
nual screening for hepatitis C for all HIV positive pa-
tients in 2005.
Patients were included if they were male, in care at the
MSHC HIV clinic, had two or more HCV antibody tests
between January 1st 2008 and 31st March 2016, their
first HCV antibody test was negative, had sexual contact
with men as their recorded risk factor for HIV acquisi-
tion and had no recorded history of injecting drug use
(IDU). The clinical files of patients who were diagnosed
with HCV infection during the study period were exam-
ined further and patients were excluded if their clinical
file contained any report of injecting drug use, or use of
blood products.
Diagnosis of HCV infection was made with either HCV
antibody testing or, in some cases was initially made
through HCV quantitative or qualitative DNA testing and
followed up with antibody testing. HCV serology was per-
formed using the Murex anti-HCV v4.0 ELISA assay with
supplementary testing by Bio-Rad Monolisa anti-HCV-2
Plus EIA. HCV qualitative polymerase chain reaction
(PCR) testing was performed using Roche Ampliprep/
Cobas Taqman qualitative test version 2.0 and HCV viral
load was performed using bDNA Bayer Version 3.0 in ac-
cordance with the Australian National Hepatitis C testing
policy [16]. Syphilis serology was performed using Rapid
Plasma Reagin (RPR) (Macro-Vue RPR card), Treponema
pallidum Particle Agglutination assay (TPPA) (Serodia
TPPA), a recombinant total antibody enzyme-linked im-
munosorbent assay (EIA) (Trepanostika TP recombinant;
and ELISA immunoassay (EIA) Bio-Merieux). From
January 2016 the Biomerieux EIA was replaced by with a
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LIASON Treponema screen (DiaSorin), an automated
chemiluminescence immunoassay. Chlamydia NAAT test-
ing was performed using the Becton Dickinson ProbeTec
strand displacement amplification assay until March 2015
and then the Aptima Combo 2 (Hologic) transmission-
mediated amplification assay.
Each HCV exposure interval was defined as the interval
between a negative HCV antibody test and the following
HCV antibody test. Each interval ended with either a
negative HCV antibody test (censor) or with a positive
HCV antibody test or HCV DNA PCR test (event). Only
HCV exposure intervals which began on or after 01
January 2008 were included in the analysis. However, re-
sults from before 01 January 2008 were used to establish
baseline measures for syphilis serology, CD4 cell counts,
HIV viral load, HBV serology and STI testing.
We used HIV viral load as a marker of successful use
of ART with virological suppression. HCV exposure in-
tervals that began on or after the date of first recorded
HIV viral load of less than 200 copies/ml were defined
as occurring after virological suppression. For immune
function, we used the most recent CD4 cell count re-
corded before the end of the HCV exposure interval.
We also included the nadir CD4 count.
We defined incident syphilis as any seroconversion
from non-reactive to reactive syphilis serology or, in the
case of syphilis re-infection, greater than 4 fold increase
in rapid plasma reagin (RPR) since most recent previous
testing. We defined incident anorectal chlamydia as a
positive or reactive Chlamydia trachomatis NAAT result
in a patient whose most recent prior NAAT result was
negative. The incident syphilis or anorectal chlamydia
diagnostic interval was the period from the most recent
negative test to the positive test.
We defined the period of HCV follow up associated
with either syphilis or chlamydia as peri-incident syphilis
or peri-incident anorectal chlamydia. It was not possible
to determine exactly when an individual acquired either
syphilis or chlamydia except that it was within the period
between a negative and positive tests. Furthermore the
HCV seroconversion window could potentially be up to
180 days after either of these infections. To account for
these two issues we conservatively assumed that it was
possible for HCV infection to have occurred up to
6 months after a positive syphilis or chlamydia test or up
to 6 months before a negative test (Fig. 1). Figure one
illustrates this graphically.
Patients were defined as ever HBV infected if there was
a positive HBV core antibody result recorded before or
during the study period and possible incident HBV if
they had a negative HBV core antibody result followed
by a positive HBV core antibody result during the study
period.
All analyses were conducted using the IBM SPSS
Statistics software package (version 23). Univariate Cox
proportional hazards regression analysis was performed
on HCV testing intervals with the following covariates:
age, country of birth, HCV exposure peri-incident syph-
ilis, HCV exposure peri-incident anorectal chlamydia,
HCV exposure after virological suppression, year of test,
possible incident HBV infection and and ever HBV in-
fected, as defined above. Multivariate Cox proportional
hazards regression analysis was performed by adjusting
for potential confounders. Covaraties with p-value < 0.20
in the univariate analysis were included in the multivari-
ate analysis.
The study was approved by the Alfred Human Ethics
Committee (approval number 189/16).
Results
Eight hundred twenty-two MSM who attended for
specialist care and were tested at least twice for HCV
antibodies between January 1st 2008 and 31st March
2016 were included after excluding 172 women, 34 men
with both IDU and MSM risk, 9 men with IDU risk only
and 316 men with other modes of HIV transmission as
their only recorded risk, and 95 men with no recorded
risk factor. The mean age of these men was 43.1 years,
Fig. 1 Definition of HCV exposure peri-incident syphilis or chlamydia. Four consecutive HCV exposure intervals in the same patient (numbered 1–4): 2,
3: These HCV exposure intervals are included as peri-incident syphilis or anorectal chlamydia: 1, 4: These HCV exposure intervals are not included as
peri-incident syphilis or anorectal chlamydia. Notes: An HCV exposure interval is the period between a negative HCV antibody test and the following
HCV antibody test. An HCV testing exposure period is peri-incident syphilis or peri-anorectal chlamydia if it overlaps with an interval extending from
180 days before to 180 days after the period between a negative syphilis or anorectal chlamydia test and an immediately following positive syphilis or
anorectal chlamydia test
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312 (38%) were born outside Australia or New Zealand
and the mean CD4 cell count nadir was 362 cells/uL.
205 men (24.9%) were diagnosed with incident syphilis
during the study period and 60 (7.3%) on two or more
occasions. See Table 1. These 822 MSM contributed
3114 person years of follow up.
We identified thirty seven cases of incident HCV in-
fection after exclusion of two further cases who reported
injecting drug use at the time of HCV diagnosis. Thirty
four of these were identified through HCV antibody test-
ing, of whom 24 went on to have positive HCV DNA
PCR. Three patients were initially diagnosed with HCV
through a positive HCV DNA test and a negative anti-
body test. Of these 37 cases, 15 had grade three liver
function test elevation at the time of diagnosis (greater
than five times the upper limit of normal), ten had grade
two (two to five times the upper limit of normal), three
had liver function test elevations less than twice the
upper limit or normal and nine had normal liver func-
tion tests.
The overall incidence of HCV infection in the study
population was 1.19/100PY (0.99–1.38). The incidence
in exposure periods temporally close to syphilis infection
(peri-incident syphilis) was 4.72/100PY (3.35–6.08) and
to anorectal chlamydia (peri-incident chlamydia) was
1.37/100PY (0.81–1.93). The incidence in men without
supressed HIV viral load was 3.19/100PY (1.89–4.49).
See Table 2.
The incidence of syphilis rose significantly from 5.3
/100PY in 2009 to 9.9/100PY in 2015(p = 0.035) and
anorectal chlamydia rose significantly from 7.2/100PY to
13.3/100PY (p = 0.037) (See Table 3 and Fig. 2).
Five patients seroconverted to HBV core antibody dur-
ing the study period. Of these, one later seroreverted to
negative HBV core antibody status, two others had high
HBV surface antibody titre that did not change before
and after core antibody seroconversion and only one had
a reactive HBV core IgM antibody result. None of these
five patients were infected with HCV during the study
period. 232 patients (28.2%) had had a reactive HBV core
antibody test at some point before or during in the study
period.
On the univariate regression analysis younger age,
higher CD4 cell count, HCV exposure intervals which
occurred before virologically suppression, and peri-inci-
dent syphilis were associated with an increased hazards
ratio for HCV acquisition. On the multivariate analysis,
only higher CD4 cell count nadir (but not most recent
CD4 cell count), younger age and peri-incident syphilis
were associated with increased risk of HCV infection.
Being born outside Australia or New Zealand, the year
of the test, incident anorectal chlamydia and HBV core
antibody status were not associated with increased risk
of HCV infection. (See Table 2).
Discussion
In this study of HIV positive MSM with no recorded
history of injecting drug use, incident HCV infection
was associated with incident syphilis infection but not
with incident anorectal chlamydia in the adjusted analysis.
Hepatitis C incidence was also associated with younger
age and higher CD4 cell count nadir. In the unadjusted
analysis, HIV viral load suppression was associated with a
reduced incidence of HCV . Furthermore, while the inci-
dence of syphilis has risen substantially over this time
period, the incidence of HCV, at least in our cohort, has
not. The stable incidence of HCV with a rising incidence
of syphilis suggests that other factors may be putting
downward pressure on hepatitis C transmission such as
greater use of HIV treatment with more HIV virally sup-
pressed individuals.
Our study was able to examine two key sets of factors
affecting the incidence of HCV infection. Firstly, we were
able to analyse HCV exposure periods that occurred near
the time of infection with syphilis and anorectal chla-
mydia. This potentially separates the biological risk
associated with syphilis from the behavioural risk asso-
ciated with both syphilis and anorectal chlamydia.
Secondly, we were able to examine CD4 cell nadir,
Table 1 Characteristics of 822 HIV-positive MSM patients during
the study period
Totala (N = 822)
Age in years, mean (±SD)b 43.1 (±12.5)
Born outside Australia or New Zealand, n (%)c 312 (38.0%)
CD4 nadir cells/uL, mean (±SD) 362 (± 186)
Years since HIV diagnosis, mean (±SD)b 6.8 (±7.2)
Never supressed viral load, n(%)d 28 (3.4%)
Any incident syphilis, n(%)e 205 (24.9%)
2 or more syphilis, n(%)e 60 (7.3%)
Any anorectal chlamydia, n(%)f 165 (20.1%)
2 or more anorectal chlamydia, n(%)f 70 (8.5%)
Number HCV tests, mean(±SD)g 3.2 (2.0)
Ever HBV infected, n(%)h 232 (28.2%)
Possible incident HBV, n(%)i 5 (0.6%)
Patient years follow-up, mean (±SD) 3.8 (±1.6)
Notes
aAll participants were MSM with no recorded history of injecting drug use
bOn the day of the first HCV antibody test
cPlace of birth outside Australia or New Zealand
dViral load greater than 200 at every testing episode within the study period
eIncident syphilis defined as change from negative to positive specific syphilis
serology or 4 fold increase in RPR during the study period
fPositive anal chlamydia NAAT test where the most recent previous negative
test was negative during the study period
gNumber of HCV antibody tests during the study period excluding the
baseline negative test
hAny positive HBVcore antibody serology at any time during the study period
iPatients with positive HBV core antibody who previously had a negative HBV
core antibody test during the study period
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virological suppression and CD4 cell nadir as covariates
in a post-HAART era cohort.
Risk factors for HCV acquisition can be studied in ei-
ther a cohort or case control study design. Case control
studies are unable to measure incidence or to determine
temporal relationship between disease and risk factors.
Our study is the second cohort to study the association
between incident syphilis infection and HCV incidence
but the first to study it in a cohort only of HIV positive
MSM with no recorded history of injecting drug use.
Furthermore it is the first cohort to study both incidence
of HCV and incidence of syphilis and anorectal chla-
mydia. Many studies with weaker designs have examined
associations between HCV acquisition, sexual behaviour
and sexually transmitted infections [4, 17–20]. However,
whether the risk is attributable to the sexual behaviour
or the sexually transmitted infection which is associated
with that behaviour remains an open question which we
sought to address in this study. A systematic review of
the risk factors for sexually transmitted HCV in HIV
positive MSM published in 2015 found only four studies
that presented adjusted estimates of risk [19–22]. Of
these four studies, two were case control studies which
showed association between HCV acquisition and sexual
behaviour [19, 20]. The other two were cohort studies
that did not specifically measure syphilis incidence. Both
published from the Swiss HIV cohort study group, they
showed association between HCV incidence, sexual be-
haviour and a past history of syphilis, but were not able
to examine incident syphilis [22]. The Multicentre AIDS
Cohort Study (MACS cohort) examined HCV incidence
in both HIV positive MSM (but not excluding those
with a history of injecting drug use) and in MSM who
have never injected (but not excluding HIV negative
MSM) and found an association between HCV risk and
both high risk behaviour and recent syphilis in the
former and in high risk behaviour but not recent syphilis
in the latter [7]. Our study found that incident syphilis
Table 2 Incidence, crude and adjusted hazards ratio for incidence HCV infection. Cox Regression Analysis
Incident HCV cases PYs Incidence (cases/100PY) Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
Total 37 3114 1.19 (0.99–1.38)
Agea 37 3193 0.61 (0.45–0.83) .002 0.67 (0.48–0.92) .014
Country of birth
Australia/New Zealand 26 1927 1.35 (1.08–1.61) 1 (ref)
Other 9 1053 0.85 (0.57–1.14) 0.64 (0.30–1.37) 0.250
CD4 count b
Most recent CD4 37 3114 1.11 (1.00–1.23) .054 1.00 (0.85–1.18) .965
Lowest CD4 c 37 3114 1.20 (0.95–1.52) .121 1.26 (1.01–1.58) .044
Year of HCV Test 37 3114 1.12 (0.94–1.34) .208
HIV viral load suppression d
No 6 188 3.19 (1.89–4.49) 1 (ref) –
Yes 31 2926 1.06 (0.87–1.25) 0.33 (0.14–0.79) .012 0.51 (0.20–1.27) .146
Exposure peri-incident syphilise
No 25 2859 0.87 (0.70–1.05) 1 (ref) -
Yes 12 254 4.72 (3.35–6.08) 5.73 (2.86–11.45) <.001 4.96 (2.46–9.99) <.001
Exposure peri-incident anorectal chlamydiaf
No 31 2676 1.16 (0.95–1.93) 1 (ref)
Yes 6 438 1.37 (0.81–1.93) 1.19 (0.49–2.84) .703
Ever HBV infectedg
No 29 2142 1.35 (1.10–1.61) 1 (ref) -
Yes 8 972 0.82 (0.53–1.11) 0.61 (0.28–1.33) .214
Notes
aAge at beginning of testing interval (HR for increments of 10 years)
bMost recent CD4 cell count before beginning of testing interval (HR for increments of 100cells/uL)
cLowest ever recorded CD4 cell count (HR for increments of 100cells/uL)
dMost recent viral load before beginning of testing interval less than 200 copies/ml
eAny testing interval overlapping with a period 180 days before the beginning and 180 days after the end of the syphilis testing interval in which incident syphilis
was diagnosed
fAny testing interval overlapping with a period 180 days before the beginning and 180 days after the end of the anorectal chlamydia testing interval in which
incident anorectal chlamydia was diagnosed
gAny testing interval in any patient ever with positive HBV core antibody
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was associated with an increased risk of HCV infection
but incident anorectal chlamydia was not. This suggests
that biological factors are responsible for the increased
risk, rather than behavioural. In addition it is biologically
plausible that HCV transmission is facilitated by genital
ulcer disease.
The association between age and the incidence of
HCV is unclear. Both an increase and decrease in the in-
cidence of HCV have been associated with increasing
age in different cohort studies [7, 22]. The case control
studies mentioned in the paragraph above controlled for
age in selecting controls and therefore could not deter-
mine an age effect [19, 20]. One cohort study observed a
lower incidence of HCV with increasing age, although
this was not discussed further [22]. The MACS cohort
showed an association between increasing age and re-
duced incidence of HCV in the full cohort but an associ-
ation between increasing age and increasing incidence of
HCV in HIV positive MSM (which did not exclude
people with a history of injecting drug use) and in
people who did not inject drugs (including HIV negative
MSM) [7]. They noted more condomless receptive anal
intercourse partners in younger MSM and in those
taking antiretroviral therapy [7]. Our study, which only
included HIV positive MSM who did not inject drugs,
observed a reduced incidence of HCV with increasing age.
Our analysis controlled for STIs which were markers of
biological and behavioural risk and for HIV virological
suppression. One possible explanation for these various
findings is that the association between age and the in-
cidence of HCV is different for sexually transmitted
and non-sexually transmitted HCV and that, when adjust-
ing for behaviour and HIV treatment, that increasing age
is in fact associated with a reduced incidence. Another
explanation is that the age effect is different in countries
or regions with different patterns of HCV epidemiology.
In countries with rising HCV incidence or prevalence,
sexual contacts of older MSM might have a higher HCV
prevalence. This effect might be less or reversed in coun-
tries, like Australia, with a stable or falling HCV incidence
or prevalence. However, an explanation for this associ-
ation remains speculative.
On multivariate analysis the only HIV disease marker
associated with a higher incidence of HCV was increased
CD4 nadir, even though both virological suppression and
a higher recent CD4 cell count were associated with an in-
creased incidence of HCV in the univariate analysis. A
Dutch case-case control study matching HCV-HIV co-
infected MSM to HIV mono-infected individuals over the
period 2009 to 2014 found an association between higher
recent CD4 cell count and HCV risk and no association
with CD4 nadir, but did not examine adjusted multivariate
estimates [5]. This case control study, however, could not
account for changes in HIV virological suppression and
Fig. 2 Incidence of HCV infection, Syphilis and Anorectal Chlamydia 2008 to 2015. Notes: Incidence was calculated only from testing intervals
beginning after January 1 2008
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CD4 cell count which occurred over time. The MACS co-
hort observed a reduced HCV risk with higher recent
CD4 cell count, but only in those with a CD4 nadir greater
than 500, but again the population was not restricted to
HIV positive MSM with no history of injecting drug use
[7]. This suggests that degree of past immunosuppression
does reduce HCV risk when adjusted for HIV virological
suppression, degree of subsequent immune recovery and
the biological and behavioural correlates of STIs. This also
raises the possibility that the relationship between sexually
transmitted HCV risk and antiretroviral therapy, recent
CD4 cell count and CD4 cell count nadir might be differ-
ent for early treated patients with high CD4 cell count
nadir than for late treated patients with low CD4 cell
count nadir. Possible mechanisms could include reduced
inflammation or genital ulceration occurring in the previ-
ously severely immunosuppressed or a role for the im-
mune response in sexual transmission of HCV other than
passive transport of HCV across a damaged membrane.
We observed no change in overall HCV incidence over
the study period. Studies in other countries have observed
an increase in incidence of both sexually transmitted
HCV and injecting transmitted HCV [21]. However, the
increase in HCV transmission in the general community
in Australia has not been observed over this period [23].
This suggests there may be an epidemiological link be-
tween HCV incidence in the general community (mostly
driven by injecting drug use) and HCV incidence in HIV
positive MSM with no history of injecting drug use. Over-
lapping of risk populations would be one such plausible
link. A further implication of this would be that successful
reduction of community HCV prevalence and incidence
through HCV treatment as prevention could translate into
reduced sexually transmitted HCV incidence in HIV posi-
tive MSM.
We did, however, observe a dramatic increase in syph-
ilis incidence over the study period. Given the increased
incidence of HCV was associated with incident syphilis,
this could be expected to have an effect at the popula-
tion level. Syphilis incidence increased more than three
times during the study period, although in our study
only 12 of 37 incident HCV cases were temporally asso-
ciated with incident syphilis. Syphilis in our study popu-
lation and in HIV positive MSM population in Australia
is continuing to rise [23]. This can be expected to offset
any reduction in HCV incidence gained through redu-
cing prevalence as a result of treatment as prevention.
Limitations
Our study is subject to certain potential limitations.
First, sexual behaviour per se was not routinely collected
in the course of clinical care at this specialist HIV clinic.
We were therefore unable to adjust for this in our ana-
lysis. For this study, we chose anorectal chlamydia as a
marker of sexual behaviour but not increased biological
risk and syphilis as a marker of both. The parallel rise in
chlamydia and syphilis incidence suggests that they are
both linked to sexual behaviour.
Secondly, although anorectal chlamydia is not usually
associated with genital ulcerations, some cases are associ-
ated with lymphogranuloma venereum chlamydia sub-
types which can be associated with ulceration. At our
centre, less than 2% of anorectal chlamydia is associated
with LGV serovars [24]. Similarly not all cases of incident
syphilis are necessarily associated with anogenital ulcer-
ation. We did not exclude LGV from cases of anorectal
chlamydia or syphilis without apparent ulceration, which
if anything would be likely to have increased the syphilis
HCV risk association and decrease the anorectal chla-
mydia HCV risk association.
Thirdly, there may have been under-reporting or under-
recording of injecting drug use at the time at which HIV
acquisition risk factors are recorded, or patients may have
commenced or ceased injecting drug use at a later time.
To minimise the bias of misclassification of injecting drug
use we additionally examined the clinical record of pa-
tients diagnosed with HCV infection and excluded two
patients who had not previously reported injecting drug
use but did so at the time of HCV diagnosis. The possibil-
ity of misclassification of the remaining patients remains
although virtually all clinicians ask about this specific risk
factor with every HCV infection.
Fourthly, patients included in this study had a high
CD4 cell count nadir. From 2009 to 2014 the CD4 cell
count threshold for intiation of ART was 500 cells/uL
and from 2014 all patients were recommended to com-
mence ART. Therefore most newly diagnosed patients
had short periods of monitoring without ART. Our
study controlled for delayed or early treatment initiation
by including virological suppression and CD4 cell count
nadir as covariates in the multivariate analysis. Previous
studies performed at an earlier time in the HIV epidemic
may have patients with much more advanced HIV infec-
tion and greater periods of observation prior to virological
suppression. Accordingly these data may not be applicable
to HCV transmission in resource limited settings or in
older cohorts where HIV patients often have lower CD4
counts and may have an immunological susceptibility to
HCV acquisition.
Fifth, very few patients were identified with possible in-
cident HBV infection in our cohort. Our previous work
has shown a low incidence of HBV infection in HIV
negative MSM of 0.2 per 100 person years [25]. Our HIV
positive population has much higher levels of vaccination
than their HIV negative peers due to an active vaccination
program. Furthermore lamivudine, tenofovir and emtraci-
tabine, the most commonly used antiretroviral drugs, are
known to have a powerful protective effect against HBV
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infection [26]. Cox regression analysis was not per-
formed on cases of possible incident HBV infection.
Our study showed a high rate of prior HBV exposure
with 28% of MSM having a recorded positive HBV core
antibody. The Australian HIV Observational Database,
a prospective cohort of people living with HIV which
includes approximately 80% men who have sex with
men reports that 44.1% of tested individuals are HBV
core antibody positive [27].
Finally, our calculation of the at-risk periods around
incident syphilis or chlamydia was greater than the ‘ac-
tual’ period over which these STIs were present. We
did this to take account of the fact that hepatitis C may
have a prolonged period of sero-conversion but by
doing this we acknowledge that actual hazard ratio is
likely to be underestimated because the denominator
period is longer. Thus it is likely that the true hazard
ratio for syphilis is actually higher than we found and
also it is possible that chlamydia has some small in-
creased risk of HCV associated with it. However under-
taking a formal prospective cohort study with frequent
STI measures to limit this would be very expensive
given the relatively low incidence of hepatitis C.
Conclusions
Hepatitis C virus infection in HIV positive MSM is associ-
ated with syphilis but not anorectal chlamydia which sug-
gests a biological rather than behavioural risk modification.
This suggests that the potential breach to the genital or
anorectal mucosa is associated with HCV risk rather than
condomless receptive anal sex per se. Rising syphilis inci-
dence will increase the periods during which the individual
is a increased risk of HCV acquisition. This may offset
declines in HCV transmission through HCV treatment as
prevention.
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